The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

Using proper running form can help prevent injuries while boosting efficiency and improving performance. Here's what you need ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin ...

Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

The PoNS device led to sustained benefits in gait function in people with multiple sclerosis in a real-world study.

Helius Medical Technologies, Inc. (Nasdaq: HSDT) has announced promising results from its PoNS Therapeutic Experience Program ...

The UPV/EHU's COMPMECH research group has patented a mechatronic instrument that uses a mobile platform to stimulate a ...

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company gained ...

NEWTOWN, Pa. - Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company with a market capitalization of $3.84 ...

Technologies announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with ...